🏥 Health Sep 17, 2026 · Geisel Communications

FDA Hearing on Psychedelic Medicine Reveals a Field Divided on the Road to Approval—Psychiatric Times

Geisel School of Medicine News
Dartmouth medical news
View Channel →
Source ↗ 👁 0 💬 0
Read article—Amber Barnato, a professor of medicine, testified Monday at an FDA public hearing on psychedelic therapies, pointing to evidence that psilocybin-assisted treatment can produce durable reductions in depression, anxiety and demoralization among patients facing life-threatening illness, but that more research is required.

Comments (0)

Sign in to join the discussion

More Like This

📰
More REM sleep linked to lower risk of 83 diseases
Health & Medicine News -- ScienceDaily · 1d ago
📰
GLP-1 weight loss and diabetes drugs linked to nutritional deficiencies in nearly 1 in 6 children
Health & Medicine News -- ScienceDaily · 1d ago
White House plan to increase control of NIH grants appears ‘dead’
STAT · 1d ago
Menopausal Hormone Therapy Thrombotic Risk Varies by Dose, Route of Administration
MedPageToday.com - medical news for physicians · 2d ago
STAT+: Nominee to lead FDA aims to speed up medical research, combat China’s rise
STAT · 2d ago
📰
Gifts from Friends provides thoughtful way to celebrate
Vanderbilt Health News · 2d ago